SNTI - Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today? | Benzinga
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.
The company plans to initiate a Phase 1 clinical trial of SENTI-202 in 2024 in ...